To develop and conduct clinical trials aimed at improving the treatment and prevention of cancer with the ultimate goal of reducing morbidity and mortality from this disease.

About Us

The Canadian Cancer Trials Group is a cooperative oncology group which carries out clinical trials in cancer therapy, supportive care and prevention across Canada and internationally. It is one of the national programmes and networks of the Canadian Cancer Society Research Institute (CCSRI), and is supported by the Canadian Cancer Society (CCS).

Faculty Researchers

Meet the Faculty Researchers


The information contained in this website is intended for use by Canadian Cancer Trials Group members at participating centres.

Recently Activated

  • ALC4 
    A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia in Adults.
  • BLC4 
    Phase II Trial of Atezolizumab in BCG-Unresponsive Non-muscle Invasive Bladder Cancer
  • BR34 
    A Randomized Trial of Durvalumab (MEDI4736) and Tremelimumab +/- Platinum Based Chemotherapy in Patients with Metastatic (Stage IV) Squamous or Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
  • CEC5 
    Corticosteroid with either Bevacizumab or Placebo for Radionecrosis after Surgery for Brain Metastases
  • GA3 
    A Randomised Phase III Double-Blind Placebo-Controlled Study of Regorafenib in Refractory Advanced Gastro-Oesophageal Cancer (AGOC)
  • I223 
    A Phase II Study of Palbociclib, A CDK4/6 Inhibitor, in Patients with Metastatic Castration-Resistant Prostate Cancer
  • I224 
    A Phase II Study of Concurrent Dabrafenib and Trametinib with Stereotactic Radiation in the Management of Patients with BRAF Mutation-Positive Malignant Melanoma and Brain Metastases
  • MA37 
    A Randomized Phase III Trial of Palbociclib with Adjuvant Endocrine Therapy versus Adjuvant Endocrine Therapy alone for HR+/HER2 Negative Early Breast Cancer
  • MAC20 
    Randomized Phase III Trial Evaluating the Role of Weight Loss In Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
  • OVC1 
    A Phase III Single-agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum-based Chemotherapy in Women with Recurrent Platinum-sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
  • OVC2 
    Phase II/III study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women with Recurrent Platinum-resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)
  • PR19 
    A Randomized Phase II Trial Evaluating High Dose Rate Brachytherapy and Low Dose Rate Brachytherapy as Monotherapy in Localized Prostate Cancer
  • Planned Trials

  • CO27 
    A Phase III, Randomised, International Trial Comparing mFOLFIRINOX Triplet Chemotherapy to mFOLFOX for high Risk Stage III Colon Cancer in Adjuvant Setting
  • CO28 
    Neoadjuvant chemotherapy and Transanal Excisional MicroSurgery in Early Rectal Cancer- The NeoTEMS Study
  • I230 
    A Phase II Trial of Durvalumab and Tremelimumab in Pretreated, Metastatic or Locally Refractory Estrogen Receptor Positive, HER2 negative Breast Cancer
  • I234 
    Prostate Cancer Biomarker Enrichment and Treatment Selection (PC_BETS) Study - Master Screening Protocol
  • MAC21 
    Aspirin for Breast Cancer (ABC): Randomized Trial of Aspirin as Adjuvant Therapy for Node Positive Breast Cancer
  • PM1 
    CAnadian Profiling and Targeted agent Utilization tRial (CAPTUR)